ES2140032T3 - Derivados de prostaglandina. - Google Patents

Derivados de prostaglandina.

Info

Publication number
ES2140032T3
ES2140032T3 ES96305966T ES96305966T ES2140032T3 ES 2140032 T3 ES2140032 T3 ES 2140032T3 ES 96305966 T ES96305966 T ES 96305966T ES 96305966 T ES96305966 T ES 96305966T ES 2140032 T3 ES2140032 T3 ES 2140032T3
Authority
ES
Spain
Prior art keywords
sub
sup
contain
formula
blood flow
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96305966T
Other languages
English (en)
Inventor
Akio Nishiura
Takuya Seko
Ryoji Matsumoto
Shin-Ichi Hamano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2140032T3 publication Critical patent/ES2140032T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

DERIVADOS ESTER DE PROSTAGLANDINA E 1 DE FORMULA (I): EN LA QUE R ES (I) -CH{SUB,2}CH{SUB,2}-O-CO-R{SUP,1} (II) -CH{SUB,2}CH{SUB,2}-O-CO-CH{SUB,2}-O-R{SUP,2}, Y R{SUP,1} Y R{SUP,2} SON, CADA UNO INDEPENDIENTEMENTE, ALQUILO C{SUB,10-20}; Y CLATRATOS DE CICLODEXTRINA DERIVADOS DE LOS MISMOS, FORMULACIONES DE LIPOSOMAS QUE LOS CONTIENEN, PROCEDIMIENTOS PARA SU PREPARACION, Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN COMO INGREDIENTE ACTIVO. LOS COMPUESTOS DE FORMULA (I), PRODUCEN EL EFECTO DE INCREMENTAR EL FLUJO SANGUINEO, Y SON UTILES PARA LA PREVENCION Y/O TRATAMIENTO DE ALTERACIONES VASCULARES PERIFERICAS, ULCERAS DE PIEL O DECUBITO, O PARA EL MANTENIMIENTO DEL FLUJO SANGUINEO.
ES96305966T 1995-08-16 1996-08-15 Derivados de prostaglandina. Expired - Lifetime ES2140032T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP23076395 1995-08-16

Publications (1)

Publication Number Publication Date
ES2140032T3 true ES2140032T3 (es) 2000-02-16

Family

ID=16912888

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96305966T Expired - Lifetime ES2140032T3 (es) 1995-08-16 1996-08-15 Derivados de prostaglandina.

Country Status (16)

Country Link
US (1) US5690957A (es)
EP (1) EP0758645B1 (es)
KR (1) KR100225689B1 (es)
CN (1) CN1058706C (es)
AT (1) ATE185559T1 (es)
AU (1) AU708905B2 (es)
CA (1) CA2183486C (es)
DE (1) DE69604631T2 (es)
DK (1) DK0758645T3 (es)
ES (1) ES2140032T3 (es)
GR (1) GR3032274T3 (es)
HU (1) HUP9602262A3 (es)
MX (1) MX9603452A (es)
NO (1) NO309086B1 (es)
TW (1) TW367324B (es)
ZA (1) ZA966934B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE112006000921T5 (de) * 2005-04-13 2008-05-08 Elan Pharma International Ltd., Athlone Nanopartikuläre Zusammensetzungen zur kontrollierten Freisetzung, die Prostaglandin-Derivate umfassen
CN1813679A (zh) * 2005-11-30 2006-08-09 上海医药(集团)有限公司 一种紫杉烷脂质体冻干组合物及其制备方法
US8916206B2 (en) * 2005-12-26 2014-12-23 Ltt Bio-Pharma Co., Ltd. Nanoparticles containing water-soluble non-peptide low-molecular weight drug
WO2007091697A2 (en) * 2006-02-07 2007-08-16 R-Tech Ueno, Ltd. Method for preparing prostaglandin derivative
WO2008139804A1 (ja) * 2007-05-14 2008-11-20 Ltt Bio-Pharma Co., Ltd. 徐放性の陰荷電基を持つ低分子薬物含有ナノ粒子
ITCA20080017A1 (it) * 2008-07-31 2010-02-01 Giuseppe Brotzu Farmaco a base di liposomi di fosfatidilcolina trasportanti una prostaglandina e1 legata alla alfa-ciclodestrina per il trattamento delle microngiopatie diabetiche e altre patologie vascolari.
CN102216310A (zh) * 2008-11-18 2011-10-12 日本株式会社Ltt生物医药 新型前列腺素e1衍生物以及包封了该前列腺素e1衍生物的纳米粒子
US8569279B2 (en) 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
JP2012528077A (ja) * 2009-05-27 2012-11-12 スキャンポ・アーゲー クローディン媒介機能の調節および皮膚疾患の処置に使用するための、プロスタグランジン誘導体を含む医薬組成物
CN102028696B (zh) * 2009-09-24 2013-02-13 上海天伟生物制药有限公司 一种前列腺素类化合物的用途
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4054736A (en) * 1970-06-10 1977-10-18 Ono Pharmaceutical Co., Ltd. Clathrate compounds of prostaglandins or their analogues with cyclodextrin
JPS59206349A (ja) * 1983-05-10 1984-11-22 Green Cross Corp:The プロスタグランジンｅ↓１誘導体

Also Published As

Publication number Publication date
GR3032274T3 (en) 2000-04-27
CA2183486A1 (en) 1997-02-17
DK0758645T3 (da) 1999-12-27
KR970010742A (ko) 1997-03-27
HU9602262D0 (en) 1996-10-28
AU708905B2 (en) 1999-08-12
TW367324B (en) 1999-08-21
HUP9602262A3 (en) 1997-08-28
HUP9602262A2 (en) 1997-05-28
EP0758645A1 (en) 1997-02-19
MX9603452A (es) 1997-03-29
ATE185559T1 (de) 1999-10-15
CA2183486C (en) 2002-03-26
US5690957A (en) 1997-11-25
AU6210596A (en) 1997-02-20
KR100225689B1 (ko) 1999-10-15
EP0758645B1 (en) 1999-10-13
NO309086B1 (no) 2000-12-11
NO963408L (no) 1997-02-17
ZA966934B (en) 1997-02-19
CN1151398A (zh) 1997-06-11
CN1058706C (zh) 2000-11-22
DE69604631T2 (de) 2000-02-17
NO963408D0 (no) 1996-08-15
DE69604631D1 (de) 1999-11-18

Similar Documents

Publication Publication Date Title
BR0015911A (pt) Derivados de benzoimidazole úteis como agentes antiproliferativos
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
ECSP941096A (es) Procedimiento para la preparacion de un derivado indol
MX9307940A (es) Nuevos derivados de la imidazopiridina, proceso para su preparacion y formulaciones farmaceuticas que los incluyen
DE69333775D1 (de) Synthetische katalytische freie radikalfänger, verwendbar als antioxidantien zur prävention und therapie von krankheiten
BR9906013A (pt) Derivados bicìclicos heteroaromáticos úteis como agentes anticancerìgenos
RU94045155A (ru) Способы ингибирования болезни альцгеймера
ES2170141T3 (es) 4-aminoderivados del acido micofenolico con actividad inmunosupresora.
TR200001542T2 (tr) Mide fundusunu gevşetici özelliklere sahip (benzodioksan, benzofuran veya benzopiran) türevleri.
ES2154844T3 (es) Derivados de hidrocalcona, composiciones cosmeticas que contienen dichos derivados y procedimientos para producir los mismos.
YU186291A (sh) Novi derivati hidroksamske kiseline i n-hidroksikarbamida
ES2140032T3 (es) Derivados de prostaglandina.
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
AR013001A1 (es) Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina.
ES2157005T3 (es) Uso del acido boswellico y sus derivados para la inhibicion de la actividad normal y elevada de la elastasa de leucocitos o de la plasmina.
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
DE69029693D1 (de) Hydantoin- oder Imidazolidintrionderivate zur Vorbeugung oder Behandlung von Niereninsuffizienz
BR0008778A (pt) Análogos de prostaglandinas seletivos para fpc16 insaturados
ES8400742A1 (es) Procedimiento de preparacion de las dibenzooxepinas sustituidas y de sus sales de adicion con un acido mineral u organi-co.
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
ATE237614T1 (de) Benzo(c)chinolizin derivate,deren herstellung und verwendung als 5-alfa-reduktase inhibitoren
AR007369A1 (es) El uso de derivados carboxilados y un medicamento que contiene uno o mas de dichos derivados
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
BR0317289A (pt) Método para tratar distúrbios do movimento usando derivados do ácido barbitúrico
DK0561882T3 (da) Hydroxamsyrederivater, som inhiberer lipoxygenase

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 758645

Country of ref document: ES